Pricing Log in Create free account

Can-Fite Biopharma Ltd (CANF) vs NeuroSense Therapeutics Ltd. (NRSN)

Can-Fite Biopharma Ltd and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Can-Fite Biopharma Ltd and NeuroSense Therapeutics Ltd. are of similar size ($6.0M and $5.6M). NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −1,148.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 6 metrics below, NeuroSense Therapeutics Ltd. leads on 4 and Can-Fite Biopharma Ltd on 2.

Valuation

Metric CANF NRSN Biotechnology median
P/E n/m n/m 8.50
P/S 0.45 n/m 9.71
P/B 0.07 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.58 n/m 0.64
EV/Sales (8.64) n/m 9.21
Earnings yield (738.94%) (406.90%) (33.15%)
Free cash flow yield (5,538.69%) (444.35%) (25.50%)

Profitability

Metric CANF NRSN Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin (1,148.62%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (56.36%)
Return on assets 0.00% 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CANF NRSN Biotechnology median
Revenue growth (TTM) (3.36%) — 6.02%
EPS growth (last fiscal year) 45.23% 18.52% 30.26%
Revenue growth, 5-year CAGR (11.90%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CANF NRSN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.60 0.28 4.72
Net debt to EBITDA 0.86 0.01 0.96

Dividend

Metric CANF NRSN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CANF NRSN Biotechnology median
Market cap 5.61m 6.01m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack